Filip Claudiu Ioan, Pîrlog Lorin-Manuel, Pătrăşcanu Andrada-Adelaida, Militaru Mariela Sanda, Iordănescu Irina, Dindelegan George Călin
Department of Plastic Surgery and Burn Unit, Emergency District Hospital, Cluj-Napoca, Romania.
First Surgical Clinic, Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Med Pharm Rep. 2025 Jul;98(3):349-357. doi: 10.15386/mpr-2898. Epub 2025 Jul 30.
BACKGROUND/OBJECTIVES: Genetic testing plays a critical role in breast cancer management by identifying individuals with high or moderate penetrance gene mutations. While clinical implications are well established, less is known about the psychological and quality-of-life impact of different genetic risk levels. This preliminary study aimed to explore whether breast cancer patients with high penetrance mutations experience different levels of distress compared to those with moderate penetrance mutations.
A total of 110 breast cancer patients treated at the Regina Maria Private Health Network in Cluj-Napoca, Romania, were included based on specific eligibility criteria. Participants completed a shortened version of the BREAST-Q questionnaire, focused on core dimensions such as emotional distress, self-concept, appearance, relationships, and financial burden. Descriptive statistics were calculated, and independent t-tests were performed to compare responses between the two genetic risk groups.
Patients with high penetrance mutations reported significantly higher distress levels in several domains, including overall emotional distress (p = 0.039), concern for daughters or relatives (p = 0.043), changes in appearance (p = 0.038), and self-concept (p = 0.043). Other factors, such as fear of diagnosis, financial burden, and impact on sexuality, did not show statistically significant differences between groups.
This preliminary study suggests that genetic risk classification may influence the psychosocial experience of breast cancer patients, with high penetrance mutation carriers experiencing greater distress in specific areas. These findings highlight the need for personalized psychosocial support based on genetic profiles and warrant further investigation in larger, longitudinal cohorts.
背景/目的:基因检测通过识别具有高或中度外显率基因突变的个体,在乳腺癌管理中发挥着关键作用。虽然临床意义已得到充分确立,但对于不同基因风险水平对心理和生活质量的影响了解较少。这项初步研究旨在探讨与中度外显率基因突变的乳腺癌患者相比,具有高外显率基因突变的患者是否经历不同程度的痛苦。
根据特定的纳入标准,纳入了罗马尼亚克卢日-纳波卡的 Regina Maria 私人健康网络治疗的 110 名乳腺癌患者。参与者完成了 BREAST-Q 问卷的简化版,重点关注情感困扰、自我概念、外貌、人际关系和经济负担等核心维度。计算描述性统计数据,并进行独立 t 检验以比较两个基因风险组之间的反应。
具有高外显率基因突变的患者在几个领域报告的痛苦水平显著更高,包括总体情感困扰(p = 0.039)、对女儿或亲属的担忧(p = 0.043)、外貌变化(p = 0.038)和自我概念(p = 0.043)。其他因素,如对诊断的恐惧、经济负担和对性的影响,在两组之间没有显示出统计学上的显著差异。
这项初步研究表明,基因风险分类可能会影响乳腺癌患者的心理社会体验,高外显率基因突变携带者在特定领域经历更大的痛苦。这些发现强调了基于基因特征提供个性化心理社会支持的必要性,并值得在更大规模的纵向队列中进行进一步研究。